Kestra Medical CEO awarded shares, sells 15,000

Kestra Medical Technologies President and CEO Brian Daniel Webster reported several Common Share transactions dated July 15, 2026.

Rhea-AI Filing Summary

Kestra Medical Technologies President and CEO Brian Daniel Webster reported several Common Share transactions dated July 15, 2026. He acquired 176,470 shares at $0.0000 per share upon full vesting of performance-based RSUs granted in 2025, then sold a total of 15,000 shares at weighted-average prices of $22.0105, $22.6333 and $23.9983, with underlying trade prices ranging from $21.45 to $24.10, under a Rule 10b5-1 trading plan adopted September 29, 2025. Following these transactions, he directly owned 556,937 Common Shares.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 4 txns

Insider Webster Brian Daniel

Role See Remarks

Sold 15,000 shs ($337K)

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	176,470	$0.00	$0.00
Sale	Common Shares F2, F3	11,216	$22.0105	$247K
Sale	Common Shares F2, F4	784	$22.6333	$18K
Sale	Common Shares F2, F5	3,000	$23.9983	$72K

Holdings After Transaction: Common Shares — 556,937 shares (Direct)

Footnotes (5)

1. F1. Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.
2. F2. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $21.45 to $22.44. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
4. F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.45 to $23.00. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
5. F5. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.49 to $24.10. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Performance RSUs vested into shares: 176,470 Common Shares Shares sold at $22.0105: 11,216 Common Shares at $22.0105 per share Shares sold at $22.6333: 784 Common Shares at $22.6333 per share +4 more

7 metrics

Performance RSUs vested into shares 176,470 Common Shares Common shares earned from PSUs granted July 17, 2025; 100% vested July 15, 2026

Shares sold at $22.0105 11,216 Common Shares at $22.0105 per share Weighted-average sale price; trades ranged from $21.45 to $22.44 on July 15, 2026

Shares sold at $22.6333 784 Common Shares at $22.6333 per share Weighted-average sale price; trades ranged from $22.45 to $23.00 on July 15, 2026

Shares sold at $23.9983 3,000 Common Shares at $23.9983 per share Weighted-average sale price; trades ranged from $23.49 to $24.10 on July 15, 2026

Total shares sold 15,000 Common Shares Aggregate of three sale transactions on July 15, 2026

Shares owned after transactions 556,937 Common Shares Direct holdings following the reported July 15, 2026 transactions

Rule 10b5-1 plan adoption date September 29, 2025 Trading plan under which the reported stock sales occurred

Key Terms

performance-based RSUs ("PSUs"), Rule 10b5-1 trading plan, weighted average price, vested

4 terms

performance-based RSUs ("PSUs") financial

"Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted..."

Rule 10b5-1 trading plan regulatory

"The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in Column 4 is a weighted average price. The prices at which the reported securities were sold..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vested financial

"100% of the PSUs vested on July 15, 2026."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did KMTS CEO Brian Daniel Webster report?

He reported acquiring 176,470 Common Shares at $0.0000 per share from vested performance-based RSUs and selling an aggregate 15,000 Common Shares in three transactions under a Rule 10b5-1 trading plan, ending with 556,937 shares held directly.

How many Kestra Medical (KMTS) shares did the CEO sell and at what prices?

Brian Daniel Webster sold 15,000 Common Shares in three trades at weighted-average prices of $22.0105, $22.6333 and $23.9983. Footnotes state the actual trade prices ranged between $21.45 and $24.10 on July 15, 2026.

What equity award did the KMTS CEO receive through performance-based RSUs?

He received 176,470 Common Shares earned from a performance-based RSU (PSU) award granted on July 17, 2025. The filing notes that 100% of these PSUs vested on July 15, 2026, converting into Common Shares at $0.0000 per share.

Were KMTS CEO Brian Daniel Webster’s stock sales made under a Rule 10b5-1 plan?

Yes. A footnote states the reported sale transactions occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. The Form 4 also indicates the Rule 10b5-1 checkbox as affirmed for these trades.

How many Kestra Medical (KMTS) shares does the CEO own after these transactions?

After the July 15, 2026 transactions, Brian Daniel Webster directly owned 556,937 Common Shares of Kestra Medical Technologies. This figure reflects the vesting of 176,470 shares from PSUs and the sale of 15,000 shares reported in the Form 4.

What do the weighted average prices mean in the KMTS CEO’s Form 4?

Each reported sale price ($22.0105, $22.6333, $23.9983) is a weighted average price. Footnotes explain that individual trades occurred within ranges of $21.45–$22.44, $22.45–$23.00, and $23.49–$24.10, and detailed breakdowns are available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 05:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/15/2026		A		176,470(1)	A	$0.00	571,937	D
Common Shares	07/15/2026	07/15/2026	S(2)		11,216	D	$22.0105(3)	560,721	D
Common Shares	07/15/2026	07/15/2026	S(2)		784	D	$22.6333(4)	559,937	D
Common Shares	07/15/2026	07/15/2026	S(2)		3,000	D	$23.9983(5)	556,937	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

2. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $21.45 to $22.44. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.45 to $23.00. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

5. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.49 to $24.10. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)